HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US2006160863A1
Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide
US2006154990A1
Use of MEK inhibitors in treating abnormal cell growth
US2006167056A1
Polymorphs of {5-[3-(4,6-Difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl)-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
CN101052633A
Methods of preparing indazole compounds
CN101094836A
Methods for preparing indazole compounds
US2006116519A1
Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester
US2005191672A1
Antisense oligonucleotides and RNA-interfering molecules targeting PAK4
CN1938017A
Therapeutic combinations
CN1897944A
Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
US2006100170A1
Isopycnic pharmaceutical formulation
US2005148643A1
Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme
US2006014821A1
Inhibitors of SARS 3C like protease
CN1829713A
3,5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US2005014137A1
Lentivirus assay system including Vif protein activity
US2005026960A1
3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US2004235952A1
Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
US2005234066A1
Alpha substituted carboxylic acids
CN1832743A
Dosage forms comprising ag013736
US2004235019A1
Diagnostics and therapeutics for the gene expression signature of PPAR-gamma receptor ligand
